Trastuzumab Monoclonal Antibody from China
Trastuzumab (Herceptin) is a humanized monoclonal antibody that inhibits HER2 protein, used in HER2-positive breast cancer therapy. Classified under HTS 3002.13.0010 as an unmixed monoclonal antibody product from biotechnological processes, supplied in bulk for pharmaceutical compounding. It regulates immunological processes via antibody targeting as defined in Chapter 30 notes.
Duty Rate — China → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Comply with USP <1046> cellular and tissue-based products standards if involving any cellular components
• Provide biotech origin certificates and endotoxin testing results to avoid quarantine at ports
• Label as 'not for retail sale' to prevent reclassification as consumer-packaged goods